Anti-inflammatory activity of angelica keiskei through suppression of mitogen-activated protein kinases and nuclear factor-κb activation pathways

Journal of Medicinal Food

Volumn 13, Issue 3, 2010, Pages 691-699

  Lee, Hyoung Joo ^a   Choi, Tae Won ^a   Kim, Hyun Jung ^a   Nam, Dongwoo ^a   Jung, Sang Hoon ^b   Lee, Eun Ha ^b   Lee, Hee Ju ^b   Shin, Eun Myoung ^c   Jang, Hyeung Jin ^a   Ahn, Kyoo Seok ^a   Shim, Bum Sang ^a   Choi, Seung Hoon ^a   Kim, Sung Hoon ^a   Sethi, Gautam ^d   Ahn, Kwang Seok ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Seoul National University   (South Korea)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angelica keiskei; cyclooxygenase 2; mitogen activated protein kinases; nitric oxide; nuclear factor B

Indexed keywords

ALKALINE PHOSPHATASE; ANGELICA EXTRACT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; GENE PRODUCT; HEXANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; PROTEIN C JUN; PROTEIN P42; PROTEIN P44; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANGELICA; ANGELICA KEISKEI; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CELL STRAIN; CELL STRAIN RAW 264 7; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ISOLATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REPRESSION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HEALTH FOOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGELICA; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOWN-REGULATION; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PLANT EXTRACTS;

ANGELICA KEISKEI;

EID: 77953800146     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.1271     Document Type: Article

References (37)

1. Aoki N, Muko M, Ohta E, Ohta S: C-geranylated chalcones from the stems of Angelica keiskei with superoxide-scavenging activity. J Nat Prod 2008;71:1308-1310.
2. Motani K, Tabata K, Kimura Y, et al.: Proteomic analysis of apoptosis induced by xanthoangelol, a major constituent of Angelica keiskei, in neuroblastoma. Biol Pharm Bull 2008;31:618-626.
3. Nishimura R, Tabata K, Arakawa M, et al.: Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol Pharm Bull 2007;30:1878-1883.
4. Ogawa H, Nakamura R, Baba K: Beneficial effect of laserpitin, a coumarin compound from Angelica keiskei, on lipid metabolism in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2005;32:1104-1109.
5. Kwon D, Yoon S, Carter O, Bailey GS, Dashwood RH: Antioxidant and antigenotoxic activities of Angelica keiskei, Oenanthe javanica and Brassica oleracea in the Salmonella mutagenicity assay and in HCT116 human colon cancer cells. Biofactors 2006;26:231-244.
6. Kimura Y, Sumiyoshi M, Baba K: Anti-tumor actions of major component 30-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation. Cancer Lett 2008;265:84-97.
7. Kimura Y, Taniguchi M, Baba K: Antitumor and antimetastatic activities of 4-hydroxyderricin isolated from Angelica keiskei roots. Planta Med 2004;70:211-219.
8. Enoki T, Ohnogi H, Nagamine K, et al.: Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei. J Agric Food Chem 2007;55:6013-6017.
9. Ogawa H, Ohno M, Baba K: Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalcone from Angelica keiskei, in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2005;32:19-23.
10. Ogawa H, Nakashima S, Baba K: Effects of dietary Angelica keiskei on lipid metabolism in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2003;30:284-288.
11. Akihisa T, Tokuda H, Hasegawa D, et al.: Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J Nat Prod 2006;69:38-42.
12. Tabata K, Motani K, Takayanagi N, et al.: Xanthoangelol, a major chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma and leukemia cells. Biol Pharm Bull 2005;28: 1404-1407.
13. Kimura Y, Baba K: Antitumor and antimetastatic activities of Angelica keiskei roots, part 1: Isolation of an active substance, xanthoangelol. Int J Cancer 2003;106:429-437.
14. Noh EJ, Ahn KS, Shin EM, Jung SH, Kim YS: Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci 2006;79:695-701.
15. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS: Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci 2005;76: 2315-2328.
16. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB: Assay for redox-sensitive transcription factor. Methods Enzymol 2000;319: 585-602.
17. Ahn KS, Moon KY, Lee J, Kim YS: Downregulation of NFkappaB activation in human keratinocytes by melanogenic inhibitors. J Dermatol Sci 2003;31:193-201.
18. Mi Jeong S, Davaatseren M, Kim W, et al.: Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NFkappaB activation in RAW 264.7 cells. Int Immunopharmacol 2009;9:319-323.
19. Ahn KS, Aggarwal BB: Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005; 1056:218-233.
20. Nakano H, Shindo M, Sakon S, et al.: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase=ERK kinase kinase-1. Proc Natl Acad Sci USA 1998;95: 3537-3542.
21. Sugii M, Ohkita M, Taniguchi M, et al.: Xanthoangelol D isolated from the roots of Angelica keiskei inhibits endothelin-1 production through the suppression of nuclear factor-kappaB. Biol Pharm Bull 2005;28:607-610.
22. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl):S81-S96.
23. Zhang W, Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9-18.
24. Choi CY, Park KR, Lee JH, et al.: Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by downregulation of NF-kappaB, ERK1=2, and p38 kinase. Eur J Pharmacol 2007;576:151-159.
25. Jijon H, Allard B, Jobin C: NF-kappaB inducing kinase activates NF-kappaB transcriptional activity independently of IkappaB kinase gamma through a p38 MAPK-dependent RelA phosphorylation pathway. Cell Signal 2004;16:1023-1032.
26. Olson CM, Hedrick MN, Izadi H, Bates TC, Olivera ER, Anguita J: p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens. Infect Immun 2007;75:270-277.
27. Craig R, Larkin A, Mingo AM, et al.: p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000;275: 23814-23824.
28. Szabo C: Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 1995;3:2-32.
29. Tinker AC, Wallace AV: Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 2006;6:77-92.
30. Akihisa T, Tokuda H, Ukiya M, et al.: Chalcones, coumarins, and flavanones from the exudate of Angelica keiskei and their chemopreventive effects. Cancer Lett 2003;201:133-137.
31. Crofford LJ, Wilder RL, Ristimaki AP, et al.: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin- 1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-1101.
32. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T: Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995;270:24965-24971.
33. Hla T, Ristimaki A, Appleby S, Barriocanal JG: Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993;696:197-204.
34. Weisz A, Oguchi S, Cicatiello L, Esumi H: Dual mechanism for the control of inducible-type NO synthase gene expression in macrophages during activation by interferon-gamma and bacterial lipopolysaccharide. Transcriptional and post-transcriptional regulation. J Biol Chem 1994;269:8324-8333.
35. Xie QW, Whisnant R, Nathan C: Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993;177:1779-1784.
36. Kim YM, Lee BS, Yi KY, Paik SG: Upstream NF-kappaB site is required for the maximal expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus lipopolysaccharide- induced RAW 264.7 macrophages. Biochem Biophys Res Commun 1997;236:655-660.
37. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK: Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 1999;20:1945-1952.